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tion,	belly	pain,	and	gas/bloating	in:	 (i)	USA	GP	sample,	 (ii)	 IBS	patients,	and	(iii)	










severe	 nausea/vomiting,	 belly	 pain,	 gas/bloating,	 and	 constipation	 (all	 P<.05).	
Women	had	more	severe	belly	pain	and	gas/bloating	than	men,	whereas	men	had	
more	severe	bowel	incontinence	(all	P<.05).

























































or	 co-	existing	 functional	 disorders.5–7	 The	 etiology	 of	 IBS	 is	 multi-
factorial,	but	the	pathogenesis	 is	thought	to	be	due	to	dysregulated	
brain–gut	 interactions	 in	which	 peripheral	 and	 central	 sensitization	
can	occur.	Central	 sensitization	at	 the	 spinal	 cord	 and	brain	 level	 is	
associated	with	increased	activation	in	brain	regions	involved	in	emo-
tional	arousal	and	pain	modulation.8
Crohn’s	 disease	 (CD)	 and	 ulcerative	 colitis	 (UC)	 are	 chronic	
immune-	mediated	disorders	classified	as	IBDs	that	affect	less	than	1%	
of	 the	USA	population.9	 Increased	 prevalence	 is	 seen	 in	 genetically	































with	 IBS,	 IBD,	 and	 the	GP,	 adjusting	 for	demographics.	We	also	as-
sess	 the	 effect	 of	 gender	 on	GI	 symptom	 severity.	We	hypothesize	














Belly pain 8 items






















•	 Understanding	 the	 differences	 in	 symptom	 severity	 be-
tween	 patients	 will	 allow	 for	 improved	 symptom	
management.
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This	 study	 recruited	 adult	 patients	 from	 a	 variety	 of	 academic	 and	








previously	 diagnosed	 with	 IBS	 seeking	 care	 at	 a	 functional	 bowel	




were	 recruited	 from	the	clinics	were	previously	diagnosed	with	 IBS	
using	the	Rome	III	criteria5	by	a	physician	with	expertise	in	IBS	before	
enrolling	 in	 this	 study.	Patients	with	 IBS	who	 responded	 to	 a	 com-
munity	advertisement	completed	a	Rome	III	questionnaire	and	under-
went	 a	medical	 history	 and	 physical	 examination	 by	 a	GI	 physician	
to	 confirm	 the	diagnosis	of	 IBS.	 In	 addition,	we	partnered	with	 the	










they	 had	 any	 concurrent	medical	 or	 psychiatric	 condition	 that	 pre-
cluded	participation.
An	additional	group	of	randomly	selected	participants	designed	to	







2.2.1 | PROMIS® GI Symptom Scales
The	 eight	 NIH	 PROMIS®	 GI	 symptom	 scales	 were	 developed	 to	
measure	 the	 breadth	 and	 depth	 of	 GI	 symptoms	 experienced	 by	
individuals	with	a	wide	range	of	digestive	disorders.	Unlike	disease-	
targeted	 measures	 for	 specific	 patient	 populations,	 the	 PROMIS® 
GI	 symptom	 scales	 were	 designed	 for	 symptom	 assessment	 in	 all	
individuals,	 whether	 within	 the	 GP	 or	 patient	 groups,	 who	 are	 ex-
periencing	 a	 GI	 symptom.	 The	 GI	 symptom	 scales	were	 developed	
following	 the	 criteria	 for	 qualitative	 and	 quantitative	 development	


























arrhea,	 29%	mixed,	 and	 11%	unknown	based	 on	Rome	 III	 criteria.5 
The	IBD	group	consisted	of	213	patients,	10%	were	of	IBD–unclas-
sified	subtype,	whereas	33%	had	Crohn’s	disease	and	57%	had	UC,	
which	 had	 previously	 been	 confirmed	 by	 accepted	 clinical,	 radio-





(P=.005),	 race/ethnicity	 (P<.0001),	 education	 level	 (P<.001),	 marital	
status	(P=.016),	and	employment	status	(P=.042).
3.2 | GI symptom differences between groups
Table	3	shows	the	comparisons	of	symptom	severity	for	each	GI	do-
main	in	patients	with	IBS	or	IBD	to	the	GP.
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IBS vs GP.	 IBS	patients	reported	significantly	worse	symptoms	of	
belly	pain	(P<.0001),	nausea	and	vomiting	(P<.0001),	gas	and	bloating	
(P<.0001),	 diarrhea	 (P<.0001),	 and	 constipation	 (P<.0001)	 than	 the	
GP.	There	were	no	significant	differences	between	patients	with	IBS	












Mean	age±SD	(years) 45±15 41±14 46±16 .008
Female	gender	(%) 68 46 57 .005
Ethnicity/race	(%)
Caucasian 56 58 73 <.0001
Hispanic 13 14 10
African-	American 18 11 12
Asian 10 11 3
Other 2.1 6.8 1.6
Education	(%)
Less	than	high	school 1.3 3.2 4.2 <.0001
High	school	graduate 33 36 60
College	graduate 37 40 26
Advanced	degree 29 21 9.9
Marital	status	(%)
Married 39 42 45 .016
Previously	married 23 15 22
Never	married 38 43 33
Employment	(%)
Employed/student 71 72 65 .042
Not	working 9.1 9.0 12
Retired 10 9.5 16






















IBS 4 182 54 9 4 –
IBD 168 14 30 1 0 –
General	
Population
– – – – – 1177
IFFGD,	 International	 Foundation	 for	 Functional	 Gastrointestinal	 Disorders;	 UCLA,	 University	 of	
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reported	 as	more	 severe	 by	 IBS	patients	 than	 IBD	patients:	 nausea	
and	vomiting	(F=22,	P<.0001),	GER	(F=32,	P<.0001),	disrupted	swal-
lowing	(F=20,	P<.0001),	belly	pain	(F=55,	P<.0001),	gas	and	bloating	
(F=42,	 P<.0001),	 and	 constipation	 (F=41,	 P<.0001).	 There	 were	 no	
significant	differences	in	the	severity	of	diarrhea	(F=0.06,	P=.80)	and	
bowel	 incontinence	 (F=0.19,	P=.69)	 between	 patients	with	 IBS	 and	
IBD	(Figure	4).









The	PROMIS®	 instruments	 are	 patient-	reported	outcome	measures	






tients	with	 IBS	and	 IBD	report	more	severe	epigastric	and	 lower	GI	
symptoms	 than	 the	GP,	but	 reported	esophageal	 symptom	severity	
that	is	comparable	or	less	severe	than	the	GP,	respectively.	Lastly,	the	
Symptom domain Subgroup Parameter P value T statistic
Gastro-	esophageal	reflux IBS 0.25 .73 0.35
IBD −4.9 <.0001 −6.5
Disrupted	swallowing IBS 0.03 .97 0.04
IBD −4.1 <.0001 −5.4
Nausea	and	vomiting IBS 3.2 <.0001 4.5
IBD −1.1 .14 −1.5
Belly	pain IBS 11.0 <.0001 15
IBD 4.2 <.0001 5.3
Gas	and	bloating IBS 8.8 <.0001 12
IBD 2.7 .0005 3.5
Diarrhea IBS 6.7 <.0001 8.5
IBD 6.9 <.0001 8.7
Bowel	incontinence IBS 1.9 .12 2.5
IBD 2.3 .004 2.9
Constipation IBS 6.9 <.0001 9.5
IBD 1.0 .21 1.3
IBD,	inflammatory	bowel	disease;	IBS,	irritable	bowel	syndrome.
































Belly pain Gas and
bloating






General population Irritable bowel syndrome
* * * *
* P <.05
*
6 of 9  |     LEE Et aL.
analysis	of	gender	differences	showed	that	overall,	women	reported	
more	 severe	 symptoms	of	 gas	 and	bloating	and	belly	pain,	 but	 less	


















tory	 and	 anatomic	 biomarkers.	The	 comparable	 severity	 of	 diarrhea	
and	bowel	incontinence	(as	opposed	to	constipation)	in	IBS	and	IBD	is	
not	unexpected	as	diarrhea	is	a	common	feature	of	both	GI	conditions.
The	 greater	 GI	 symptom	 severity	 seen	 in	 IBS	 patients	 is	 likely	
multifactorial.	 Patients’	 illness	 experience	 reflects	 upon	 how	 they	
perceive	their	sickness	in	the	context	of	psychosocial	and	demographic	
conditions.31	 IBS	 is	 a	 stress-	sensitive	 disorder	 in	which	 stress	 is	 as-
sociated	with	enhanced	colonic	motility	and	enhanced	visceral	percep-
tion.32,33	Hypervigilance,	an	 increased	attention	to	noxious	stimuli,	or	







and	 the	GP.	Prior	brain	 imaging	studies	have	suggested	 that	patients	
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Disrupted 
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** ** * *
Disrupted 
swallowing

















with	 IBS	will	 also	 report	 coexisting	 symptoms	 of	 GER,39,40	 but	 the	
prevalence	of	IBD	patients	reporting	GER	symptoms	has	not	been	well	
studied.	 In	 the	GP,	 the	prevalence	of	GER	ranges	from	10%	to	20%	
in	Western	 populations.41	A	 possible	 explanation	 for	 the	 decreased	
















outpatients,	which	 included	our	patients	with	 IBS	 and	 IBD	but	 also	
others	with	diverse	GI	conditions	and	systemic	sclerosis,	had	worse	
regurgitation	but	similar	heartburn	symptoms	than	the	GP	using	the	
PROMIS®	GI	 Symptom	 items.17	The	prior	 inclusion	of	patients	with	
gastro-	esophageal	reflux	disease	(GERD)	and	systemic	sclerosis,	which	
commonly	 coexists	 with	 GERD,	 with	 GI	 symptoms	 in	 the	 previous	
study	likely	explains	these	differing	results.	Further	studies	should	be	





















incontinence	 from	mucoid-	type	 stools.49,50	Our	 finding	 that	women	




Our	 study	 has	 limitations.	We	 do	 not	 have	 information	 on	 the	
number	of	patients	with	IBD	who	also	would	concomitantly	meet	di-
agnostic	criteria	for	IBS.	A	recent	meta-	analysis	found	that	up	to	42%	








ent	demographic	differences	 in	 these	diseases	or	may	be	 related	 to	
way	these	patients	were	recruited.	However,	our	analyses	controlled	
for	 these	demographic	 differences.	As	many	of	 these	patients	were	






recruited	 from	a	mailing	 list	may	be	more	hypervigilant	and	 tend	 to	
report	more	 severe	 symptoms,	 however,	 only	 a	 very	 small	minority	
of	patients	were	recruited	in	this	manner.	In	the	case	of	IBD,	further	
studies	that	could	stratify	a	patient’s	IBD	symptoms	based	on	inflam-
matory	 biomarker	 levels,	 such	 as	C-	reactive	 protein	 or	 calprotectin,	
would	be	useful	to	help	confirm	our	findings.	Another	limitation	is	that	







and	 the	GP.	This	 study	 is	 unique	 in	 its	 ability	 to	 compare	 symptom	
perception	 in	 these	 disorders,	 and	 highlights	 the	 importance	of	 un-
derstanding	 the	 impact	of	brain–gut	 interactions	 in	GI	 symptom	as-
sessment.	Although	most	physicians	will	treat	objective	signs	of	IBD	
intestinal	 inflammation,	 IBS	 symptom	severity	may	not	primarily	 re-
flect	macroscopic	 or	microscopic	 inflammation,	 but	may	 rather	 rep-
resent	central	amplification	of	viscerosensory	input.	In	fact,	symptom	




markers	than	other	severity	 instruments	 in	 IBS	and	 IBD,	but	 further	
studies	 are	 needed.	 Future	 studies	 should	 also	 include	 prospective	
assessment	 of	 symptom	 severity	 in	well-	characterized	 IBS	 and	 IBD	
patients	to	confirm	our	findings,	and	also	determine	if	these	symptom	
scales	are	responsive	to	treatment	effects.
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